A CNBC story doing the rounds over......>

MARKET TALK: A CNBC story doing the rounds over the last few minutes "Moderna's

potential vaccine to prevent Covid-19 produced a "robust" immune response in all

45 patients in its early stage human trial, providing more promising data that

the vaccine may give some protection against the coronavirus, according to newly

released data published Tuesday evening in the peer-reviewed New England Journal

of Medicine...All 45 patients produced neutralizing antibodies, which scientists

believe are important for gaining protection against the virus. In the trial,

each participant received a 25, 100 or 250 microgram dose, with 15 people in

each dose group. Participants received two doses of the potential vaccine. After

two vaccinations, the vaccine elicited a "robust" immune response in all

participants in all dose cohorts, Moderna said. The company said the levels of

neutralizing antibodies in patients in the high dose group were fourfold higher

than in recovered Covid-19 patients."